Login
About Alexion
Our Leadership
Our Partnerships
Our Ethical Standards
Our History
Patient Focus
Advocacy
Patient Stories
Products
Soliris
®
PNH
aHUS
Strensiq
®
Kanuma
®
Research & Development
Our Pipeline
Development Programs
Investigator-Sponsored Research
Discovery Partnerships
Responsibility
Global Access to Medicines Policy
Main Menu
Careers
Job Opportunities
Why Choose Alexion
Culture
Compensation & Benefits
Work/Life Balance
Health & Wellness
Financial Security
Recognition & Rewards
Personal Growth & Development
Professional Development
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Select a Country
Investors
News
Contact
Search for:
North America
Canada
United States
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
United Kingdom
Asia Pacific
Australia
China
India
Japan
About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Home
»
Newsroom
»
Press Releases
Press Releases
Press Releases
Filter by Category
All Press Releases
Company Releases
Company Statements
Financial Releases
Product Releases
Sort by Year
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Media
Inquiries
Media
Materials
Email
Alerts
All News Releases
Search:
Alexion Pharmaceuticals to Report Third Quarter 2016 Results on Thursday, October 27, 2016
October 10, 2016
HTML
PDF
New Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important Markers of Liver Injury and Lipid Abnormalities in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa)
October 6, 2016
HTML
PDF
Alexion Employees Volunteer Together in Company’s First Global Day of Service
September 23, 2016
HTML
PDF
Alexion Launches Uncommon Strength Campaign to Unite and Celebrate the Courage and Resilience of People Living with Rare Diseases
September 13, 2016
HTML
PDF
Alexion to Present at Upcoming Investor Conferences
September 6, 2016
HTML
PDF
European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
August 29, 2016
HTML
PDF
Alexion Reports Second Quarter 2016 Results
July 28, 2016
HTML
PDF
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)
July 14, 2016
HTML
PDF
Alexion Pharmaceuticals to Report Second Quarter 2016 Results on Thursday, July 28, 2016
July 11, 2016
HTML
PDF
New Data from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress
July 7, 2016
HTML
PDF
« first
‹ previous
…
11
12
13
14
15
16
17
18
19
…
next ›
last »
